Samsung Biologics
Samsung Biologics, a leading player in the biopharmaceutical industry, is headquartered in Incheon, South Korea (KR). Founded in 2011, the company has rapidly established itself as a key provider of contract development and manufacturing services (CDMO) for biopharmaceuticals, catering to a global clientele. With a focus on monoclonal antibodies and other biologics, Samsung Biologics offers unique solutions that leverage cutting-edge technology and state-of-the-art facilities. The company has achieved significant milestones, including the completion of its third manufacturing plant, which enhances its production capacity and reinforces its market position. Recognised for its commitment to quality and innovation, Samsung Biologics continues to set industry standards, making it a preferred partner for biopharmaceutical companies worldwide.
DitchCarbon Score
How does Samsung Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsung Biologics's score of 43 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsung Biologics's reported carbon emissions
In 2023, Samsung Biologics reported total carbon emissions of approximately 754,473,000 kg CO2e, comprising 1,209,000 kg CO2e from Scope 1, 5,086,000 kg CO2e from Scope 2, and 528,480,000 kg CO2e from Scope 3 emissions. This marked a significant commitment to sustainability, as the company aims for net zero emissions by 2050 or earlier. To achieve this goal, Samsung Biologics has set ambitious reduction targets: a 32% reduction in direct emissions by 2030 and a 62% reduction by 2040, using 2022 as the baseline year. Additionally, the company plans to reduce emissions from suppliers by 36% by 2030 and 73% by 2040. These initiatives reflect Samsung Biologics's dedication to addressing climate change and enhancing its environmental performance within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 41,793,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 83,014,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsung Biologics is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
